Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. more
Time Frame | ZVSA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.79% | -3.39% | -3.47% |
1-Month Return | -11.29% | -3.25% | -0.29% |
3-Month Return | -54.73% | -11.61% | 4.5% |
6-Month Return | -78.22% | -5.89% | 6.91% |
1-Year Return | -89.72% | 2.65% | 23.79% |
3-Year Return | 3042.86% | 0.56% | 28.43% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | 10.40K | 10.40K | 10.40K | 10.40K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | (10.40K) | (10.40K) | (10.40K) | (10.40K) | [{"date":"2020-12-31","value":-1040000,"profit":false},{"date":"2021-12-31","value":-1040000,"profit":false},{"date":"2022-12-31","value":-1040000,"profit":false},{"date":"2023-12-31","value":-1040000,"profit":false}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 11.83M | 7.70M | 13.01M | 14.41M | [{"date":"2020-12-31","value":82.11,"profit":true},{"date":"2021-12-31","value":53.46,"profit":true},{"date":"2022-12-31","value":90.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (11.83M) | (7.70M) | (13.01M) | (14.42M) | [{"date":"2020-12-31","value":-1183305800,"profit":false},{"date":"2021-12-31","value":-770437600,"profit":false},{"date":"2022-12-31","value":-1301306400,"profit":false},{"date":"2023-12-31","value":-1442077400,"profit":false}] | |
Total Non-Operating Income/Expense | (1.37M) | (1.20M) | (2.79M) | (93.38M) | [{"date":"2020-12-31","value":-136655800,"profit":false},{"date":"2021-12-31","value":-120115100,"profit":false},{"date":"2022-12-31","value":-279301700,"profit":false},{"date":"2023-12-31","value":-9338216900,"profit":false}] | |
Pre-Tax Income | (12.68M) | (8.08M) | (14.05M) | (107.75M) | [{"date":"2020-12-31","value":-1268316600,"profit":false},{"date":"2021-12-31","value":-808416100,"profit":false},{"date":"2022-12-31","value":-1404760700,"profit":false},{"date":"2023-12-31","value":-10775377600,"profit":false}] | |
Income Taxes | 516.45K | 821.37K | 745.05M | (9.46M) | [{"date":"2020-12-31","value":0.07,"profit":true},{"date":"2021-12-31","value":0.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1.27,"profit":false}] | |
Income After Taxes | (13.20M) | (8.91M) | (759.10M) | (98.30M) | [{"date":"2020-12-31","value":-1319961600,"profit":false},{"date":"2021-12-31","value":-890552700,"profit":false},{"date":"2022-12-31","value":-75909760700,"profit":false},{"date":"2023-12-31","value":-9829794600,"profit":false}] | |
Income From Continuous Operations | (12.68M) | (8.08M) | (14.05M) | (89.56M) | [{"date":"2020-12-31","value":-1268316600,"profit":false},{"date":"2021-12-31","value":-808416100,"profit":false},{"date":"2022-12-31","value":-1404760700,"profit":false},{"date":"2023-12-31","value":-8956172800,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (13.20M) | (8.91M) | (759.10M) | (98.30M) | [{"date":"2020-12-31","value":-1319961600,"profit":false},{"date":"2021-12-31","value":-890552700,"profit":false},{"date":"2022-12-31","value":-75909760700,"profit":false},{"date":"2023-12-31","value":-9829794600,"profit":false}] | |
EPS (Diluted) | - | - | (180.38) | (19.12) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-18038.42,"profit":false},{"date":"2023-12-31","value":-1912.04,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
ZVSA | |
---|---|
Cash Ratio | 10.65 |
Current Ratio | 33.83 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ZVSA | |
---|---|
ROA (LTM) | -24.92% |
ROE (LTM) | -152.23% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ZVSA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.64 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.36 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ZVSA | |
---|---|
Trailing PE | 0.00 |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.34 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
ZyVersa Therapeutics Inc. (ZVSA) share price today is $1.235
Yes, Indians can buy shares of ZyVersa Therapeutics Inc. (ZVSA) on Vested. To buy ZyVersa Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZVSA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of ZyVersa Therapeutics Inc. (ZVSA) via the Vested app. You can start investing in ZyVersa Therapeutics Inc. (ZVSA) with a minimum investment of $1.
You can invest in shares of ZyVersa Therapeutics Inc. (ZVSA) via Vested in three simple steps:
The 52-week high price of ZyVersa Therapeutics Inc. (ZVSA) is $13.4. The 52-week low price of ZyVersa Therapeutics Inc. (ZVSA) is $0.98.
The price-to-earnings (P/E) ratio of ZyVersa Therapeutics Inc. (ZVSA) is 0.002
The price-to-book (P/B) ratio of ZyVersa Therapeutics Inc. (ZVSA) is 0.34
The dividend yield of ZyVersa Therapeutics Inc. (ZVSA) is 0.00%
The market capitalization of ZyVersa Therapeutics Inc. (ZVSA) is $2.36M
The stock symbol (or ticker) of ZyVersa Therapeutics Inc. is ZVSA